Drugs / AMSILAROTENE
AMSILAROTENE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00077142 | Apr 2001 → Jul 2005 | liver cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00756782 | Oct → Dec 2008 | hepatocellular carcinoma | Taiho Oncology, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00687596 | Aug 2008 → May 2010 | hepatocellular carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00667628 | Apr 2008 → Dec 2009 | hepatocellular carcinoma | Taiho Oncology, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMSILAROTENE | ChEMBL registry synonym — accepted as the source's own label CHEMBL32994 ↗ |
| Known as | AM-555S | ChEMBL registry synonym — accepted as the source's own label CHEMBL32994 ↗ |
| Known as | TAC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00756782 ↗ |
| Modality | Small molecule | “A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.” PMID 18504614 ↗ May 2008 |
| Route | Oral | “Patients receive oral TAC-101 once daily on days 1-14.” NCT00077142 ↗ |